# US 2020/0140887 A1 · Viral Delivery of RNA Utilizing Self-Cleaving Ribozymes and CRISPR-Based Applications Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0140887 A1
- Document ID: US20200140887A1
- Status: Published application
- Kind: A1
- Application number: 16/311,887
- Filed: 2017-06-22
- Published: 2020-05-07
- Earliest claimed: 2016-06-22
- Assignees: Icahn School of Medicine at Mount Sinai
- Applicants: Icahn School of Medicine at Mount Sinai
- Inventors: Arnold Park; Benhur Lee; Ruth Watkinson
- Web page: https://patentgrep.com/patent/US20200140887A1

## CPC

- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- C12N 15/86: Viral vectors
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 9/224: {Class 1 CAS enzyme complex, e.g. multi-enzyme}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N 2310/12: catalytic nucleic acids, e.g. ribozymes
- C12N 2310/121: Hammerhead
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2760/10121: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2760/18843: viral genome or elements thereof as genetic vector
- C12N 2800/80: Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present disclosure relates to viral delivery of RNA utilizing self-cleaving ribozymes and applications of such, including but not limited to CRISPR-Cas related applications.

## Claims

### Claim 1

A nucleic acid comprising a genome sequence of a single-stranded RNA (ssRNA) virus or antigenome sequence that is complementary to the genome sequence, the antigenome sequence comprising a first region comprising
(i) a target segment, and
(ii) a first segment encoding a first self-cleaving ribozyme, wherein the target segment is adjacent to the first segment.

### Claim 2 (depends on 1)

The nucleic acid of claim 1, wherein the first region further comprises (iii) a second segment encoding a second self-cleaving ribozyme, wherein the target segment is flanked by the first segment and the second segment.

### Claim at position 3

3-4. (canceled)

### Claim 5 (depends on 1)

The nucleic acid of claim 1, wherein the first self-cleaving ribozyme is a 3′ self-cleaving ribozyme or a 5′ self-cleaving ribozyme.

### Claim 6

(canceled)

### Claim 7 (depends on 1)

The nucleic acid of claim 1, wherein the antigenome sequence further comprises a second region comprising a third segment encoding a nuclease.

### Claim 8 (depends on 7)

The nucleic acid of claim 7, wherein the second region further comprises a fourth segment encoding a reporter molecule.

### Claim 9 (depends on 1)

The nucleic acid of claim 1, wherein the target segment comprises guide RNA (gRNA), wherein the gRNA has a scaffold sequence and a targeting sequence.

### Claim 10 (depends on 7)

The nucleic acid of claim 7, wherein the nuclease comprises Cas9 or Cpf1.

### Claim 11

(canceled)

### Claim 12 (depends on 1)

The nucleic acid of claim 1, wherein the first self-cleaving ribozyme comprises a hammerhead ribozyme.

### Claim 13 (depends on 5)

The nucleic acid of claim 5, wherein the first self-cleaving ribozyme comprises one of a hammerhead ribozyme and a hepatitis delta virus (HDV) ribozyme.

### Claim 14 (depends on 1)

The nucleic acid of claim 1, further comprising a third region comprising a fifth segment, wherein the fifth segment comprises a mutant P gene.

### Claim 15 (depends on 1)

The nucleic acid of claim 1, further comprising a fourth region comprising a fourth region comprising a sixth segment, wherein the sixth segment comprises a mutant L gene.

### Claim 16 (depends on 1)

A viral particle comprising the nucleic acid of claim 1.

### Claim at position 16

17-18. (canceled)

### Claim 19 (depends on 16)

The viral particle of claim 16 wherein the viral particle is within the order mononegavirales.

### Claim 20 (depends on 16)

The viral particle of claim 16 wherein the viral particle is within the family paramyxoviridae.

### Claim 21 (depends on 16)

The viral particle of claim 16 wherein the viral particle is a Sendai virus (SeV) or a Newcastle disease virus (NDV).

### Claim 22

(canceled)

### Claim 23 (depends on 1)

The viral particle of claim 1 wherein the viral particle is a temperature sensitive mutant.

### Claim 24

(canceled)

### Claim 25 (depends on 16)

A method of introducing into a host cell a target RNA, comprising
(i) contacting the viral particle of claim 16 with said host cell; and
(ii) culturing the host cell under conditions allowing
(a) producing a target RNA; and
(b) liberating the target RNA, wherein the first self-cleaving ribozyme liberates the target RNA from the transcribed first region.

### Claim 26 (depends on 25)

The method of claim 25 wherein the host cell is selected from the group consisting of an archaea cell, bacterial cell, and a eukaryotic cell.

### Claim 27 (depends on 26)

The method of claim 26, wherein the host cell is a stem cell.

### Claim 28 (depends on 16)

A method of introducing a site-specific modification to target DNA in a host cell comprising
(i) contacting the viral particle of claim 16 with said host cell;
(ii) culturing the host cell under conditions allowing
(a) producing the gRNA flanked by the 5′ self-cleaving ribozyme and the nuclease;
(b) liberating the gRNA, wherein the 5′ self-cleaving ribozyme liberates the gRNA,
(c) expressing the nuclease;
(d) forming a complex between the nuclease and the gRNA, wherein the scaffold sequence of the gRNA is bound to the nuclease; and
(e) contacting the target DNA with the complex, wherein the targeting sequence of the gRNA binds to a sequence on the target DNA adjacent to a protospacer adjacent motif (PAM); and
(iii) introducing the site-specific modification to the target DNA.

### Claim 29 (depends on 28)

The method of claim 28, wherein the site-specific modification is one of an insertion, a deletion, a frameshift, and a point mutation.

### Claim 30 (depends on 28)

The method of claim 28 wherein the DNA is genomic.

### Claim 31 (depends on 28)

The method of claim 28 wherein the host cell is selected from the group consisting of an archaea cell, bacterial cell, and a eukaryotic cell.

### Claim at position 30

32-41. (canceled)
